Whalesbook
Demerger ka Poora Plan
Natco Pharma ke board ne decision le liya hai ki wo agrochemicals waale business ko completely alag karenge aur ek nayi company banayenge jiska naam hoga Natco Crop Health Sciences Ltd. Yeh split October 1, 2026 se kaam karega. Shareholders ko bada fayda yeh hai ki unhe Natco Pharma ke har share ke peeche Natco Crop Health Sciences ka ek share milega. Is 1:1 share swap se shareholders ko dono businesses mein seedha ownership milegi. Natco Pharma khud is nayi company mein around 20% stake rakhegi taaki strategic support de sake. Is move ka main reason hai ki dono pharma aur agrochem divisions ko alag alag focus mile, unki value unlock ho, aur wo independently grow kar sakein.
Kahan Kahan Farak Aayega? Valuation Ka Game
Aapko bata dein, Natco Pharma ke shares March 24, 2026 ko ₹948.00 par close hue, jo 2.18% upar tha. Matlab market ko kuch toh achha lag raha hai. Par agar agrochemicals business ki baat karein, toh FY25 mein isne sirf ₹60.62 crore ka revenue diya, jo total ka sirf 1.48% tha. Indian pharma sector 2026 mein 7.8-8.1% ke CAGR se badh raha hai, jabki Indian agrochemicals market 2025 se 2030 tak 13% CAGR se grow hone ka expect hai.
Ab valuation gap dekho: Natco Pharma ka P/E ratio around 11.11x hai (March 2026 tak). Yeh compared to peers jaise Sun Pharmaceutical Industries (38.77x), Divi's Laboratories (65.35x), aur Cipla (22.32x) bahut kam hai. Jabki company ki market cap March 2026 tak around ₹171.20 billion thi. Issi valuation gap ko sort karne ke liye yeh demerger kiya ja raha hai taaki pharma business ki asli value dikh sake.
Naye Plans aur Focus Area
Is split ka matlab hai ki Natco Pharma apna core pharma business (oncology, cardiology, neurology etc.) ko agrochemical segment (pesticides, herbicides) se alag karegi. Pharma unit ko better valuation milne ki ummeed hai, bina agrochemical division ke pressure ke. Iske saath hi, company ek nai Nigerian subsidiary, Natco Pharma Nigeria Ltd, bhi bana rahi hai jismein $100,000 tak ka investment hoga. Aur jo Australia waali subsidiary hai, Natco Pharma Australia Pty Ltd, use September 2026 tak band kar diya jayega.
Regulatory Issues Ka Kya?
Natco Pharma kuch regulatory scrutiny se guzar rahi hai. U.S. Food and Drug Administration (FDA) ne unke manufacturing sites par kuch observations diye hain (Form 483). Jaise ki Kothur facility mein cleanliness aur sterility ko lekar November 2023 mein issues aaye the. Chennai API facility mein bhi November 2025 mein 7 observations mile, jo US mein product approvals par asar daal sakte hain. Telangana plant mein bhi April 2024 mein violations the. Pichhle records mein bhi patent litigation aur substandard drug sales ke mamle rahe hain. Achhi baat yeh hai ki company lagbhag debt-free hai aur financials strong hain, par yeh regulatory cheezein dhyaan dene wali hain.
Future Outlook
Analyst log abhi Natco Pharma ko 'Hold' rating de rahe hain aur unka average price target ₹904 ke aas paas hai. Thoda cautious view hai kyunki demerger ka pura impact abhi clear nahi hai aur regulatory issues bhi hain. Company ke liye sabse badi challenge hai FDA observations ko manage karna aur apne R&D ko specialized areas mein use karna.